Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura

被引：14
|
作者：
Bhoopalan, Senthil Velan [1 ]
Hankins, Jane [1 ]
George, James [2 ]
Ryder, Alex [3 ]
Onder, Ali Mirza [3 ]
Puri, Latika [1 ]
机构：
[1] St Jude Childrens Res Hosp, 262 Danny Thomas Pl, Memphis, TN 38105 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[3] Le Bonheur Childrens Hosp, Memphis, TN USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷 / 07期
关键词：
ADAMTS13; caplacizumab; refractory TTP; thrombocytopenia; TTP; vWF;
D O I：
10.1002/pbc.27737
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
    Reid, Justin H.
    Durant, Karin M.
    Chen, Sheh-Li
    Perissinotti, Anthony J.
    King, Richard
    Khoriaty, Rami
    Marini, Bernard L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1695 - 1702
  • [32] Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment
    le Besnerais, Maelle
    Veyradier, Agnes
    Benhamou, Ygal
    Coppo, Paul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1127 - 1134
  • [33] Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
    Goshua, George
    Sinha, Pranay
    Hendrickson, Jeanne E.
    Tormey, Christopher
    Bendapudi, Pavan K.
    Lee, Alfred Ian
    BLOOD, 2021, 137 (07) : 969 - 976
  • [34] USE OF CAPLACIZUMAB IN SPAIN, ANALYSIS OF THE SPANISH REGISTRY OF THROMBOTIC THROMBOCYTOPENIC PURPURA (REPTT)
    Maria Eva, Mingot Castellano
    Ana, Kerguelen
    Peinado Jose, Garcia-Arroba
    Joan, Cid
    Maria Moraima, Jimenez
    Segui Ines, Gomez
    Paz, Martin
    Rosa, Goterris
    Luis, Hernandez
    Inma, Tallon
    Sara, Varea
    Aurora, Viejo
    Docampo Marta, Fernandez
    Munoz Nadia, Garcia
    Miriam, Vara
    Miguel, Fernandez
    Candel Faustino, Garcia
    Maria Liz, Paciello
    Garma Julio, Del Rio
    Izquierdo Cristina, Pascual
    HAEMATOLOGICA, 2021, 106 (10) : 105 - 106
  • [35] Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
    Cilla, Nicolas
    Dallemagne, Julie
    Vanhove, Marie
    Stordeur, Patrick
    Motte, Serge
    De Wilde, Virginie
    JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 84 - 88
  • [36] Refractory thrombotic thrombocytopenic purpura
    Herfurth, K.
    Ruhe, J.
    Kentouche, K.
    Guenther, A.
    Braemer, D.
    Eckardt, N.
    Busch, M.
    Wolf, G.
    INNERE MEDIZIN, 2022, 63 (12): : 1307 - 1311
  • [37] More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
    Picod, Adrien
    Benhamou, Ygal
    Bouzid, Raida
    Veyradier, Agnes
    Coppo, Paul
    BLOOD ADVANCES, 2023, 7 (12) : 2678 - 2680
  • [38] Use of Rituximab in acute refractory thrombotic thrombocytopenic purpura
    Scully, M
    Starke, R
    Flynn, M
    Haggar, D
    Mackie, I
    Machin, S
    Cohen, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 45 - 45
  • [39] Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus
    Nagel, Margaret B.
    Ryder, Alex
    Lobbins, Monica
    Bhatt, Nidhi
    PEDIATRIC BLOOD & CANCER, 2021, 68 (01)
  • [40] Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab
    Aggarwal, Vibhuti
    Singer, Zachary
    Ledingham, Donna
    Othman, Ibraheem
    HEMATOLOGY, 2021, 26 (01) : 590 - 593
12345